Gastric peroral endoscopic myotomy for compassionate treatment of symptomatic gastroparesis in patients on chronic opioids

It has been estimated that nearly half of patients with gastroparesis use opioids long term, are unable to cease or wean opioid use, and continue to endorse debilitating symptoms. The aim of this study was to evaluate outcomes of gastric peroral endoscopic myotomy (G-POEM) as compassionate treatment in patients with gastroparesis who are unable to discontinue long-term opioid use. This was a multicenter retrospective analysis of prospective databases containing patients with gastroparesis taking opioids who underwent G-POEM between January 2021 and November 2024. Functional luminal imaging probe (FLIP) pyloric measurements were obtained pre- and post-G-POEM at follow-up. Clinical response to G-POEM was defined as improvement of ≥1 point on the Gastroparesis Cardinal Symptom Index. Thirty-eight patients with gastroparesis on opioids with a median follow-up of 6 months (range, 3-18 months) underwent G-POEM during the study period. Technical success was 100%. Clinical success was achieved in 60.5% (23/38) of the patients. There were no differences in demographics, symptom duration, etiology of gastroparesis, baseline Gastroparesis Cardinal Symptom Index score, gastric-emptying scintigraphy or daily morphine milligram equivalent between responders and nonresponders. When compared with nonresponders, patients who responded to G-POEM had a significantly lower FLIP baseline pyloric diameter (13.2 [standard deviation (SD) 3.4 mm 2 ] vs 15.6 [SD 2.7 mm 2 ]; P = .04) and distensibility index (4.8 [SD 1.9 mm 2 /mm Hg] vs 8.4 [SD 4.6 mm 2 /mm Hg]; P = .004). Clinical response was associated with improvement in FLIP pyloric diameter and distensibility index. This study suggests that G-POEM could be considered as a safe and effective compassionate treatment in select patients with gastroparesis who are taking opioids long term, particularly those with lower pyloric compliance on physiologic testing. Future studies are needed to corroborate these preliminary findings.

Authors

Institutions

Publication Details

Journal
iGIE
Published
2025-05-01
DOI
https://doi.org/10.1016/j.igie.2025.05.001
Citations
1
Primary Topic
Gastrointestinal motility and disorders
Type
article
Field-Weighted Citation Impact
1.81
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Gastric peroral endoscopic myotomy for compassionate treatment of symptomatic gastroparesis in patients on chronic opioids

Aimen Farooq, Kambiz S. Kadkhodayan, Abdullah A. Abbasi, Saurabh Chandan et al.
1 citations
iGIE
Gastrointestinal motility and disorders
1.81
article

Gastric peroral endoscopic myotomy for compassionate treatment of symptomatic gastroparesis in patients on chronic opioids

Aimen Farooq, Kambiz S. Kadkhodayan, Abdullah A. Abbasi, Saurabh Chandan, Deepanshu Jain, Maham Hayat, Irteza Inayat, Yasi Xiao, Mustafa A. Arain, Muhammad K. Hasan, Abel Joseph, Joo Ha Hwang, Dennis J. Yang, Sagar Pathak, Natalie Danielle Cosgrove, Ernesto Robalino Gonzaga, Bani Fawwaz BahaAldeen
article en
1 citations

Abstract

It has been estimated that nearly half of patients with gastroparesis use opioids long term, are unable to cease or wean opioid use, and continue to endorse debilitating symptoms. The aim of this study was to evaluate outcomes of gastric peroral endoscopic myotomy (G-POEM) as compassionate treatment in patients with gastroparesis who are unable to discontinue long-term opioid use. This was a multicenter retrospective analysis of prospective databases containing patients with gastroparesis taking opioids who underwent G-POEM between January 2021 and November 2024. Functional luminal imaging probe (FLIP) pyloric measurements were obtained pre- and post-G-POEM at follow-up. Clinical response to G-POEM was defined as improvement of ≥1 point on the Gastroparesis Cardinal Symptom Index. Thirty-eight patients with gastroparesis on opioids with a median follow-up of 6 months (range, 3-18 months) underwent G-POEM during the study period. Technical success was 100%. Clinical success was achieved in 60.5% (23/38) of the patients. There were no differences in demographics, symptom duration, etiology of gastroparesis, baseline Gastroparesis Cardinal Symptom Index score, gastric-emptying scintigraphy or daily morphine milligram equivalent between responders and nonresponders. When compared with nonresponders, patients who responded to G-POEM had a significantly lower FLIP baseline pyloric diameter (13.2 [standard deviation (SD) 3.4 mm 2 ] vs 15.6 [SD 2.7 mm 2 ]; P = .04) and distensibility index (4.8 [SD 1.9 mm 2 /mm Hg] vs 8.4 [SD 4.6 mm 2 /mm Hg]; P = .004). Clinical response was associated with improvement in FLIP pyloric diameter and distensibility index. This study suggests that G-POEM could be considered as a safe and effective compassionate treatment in select patients with gastroparesis who are taking opioids long term, particularly those with lower pyloric compliance on physiologic testing. Future studies are needed to corroborate these preliminary findings.

iGIE
AdventHealth Orlando (US), Florida Hospital Medical Group (US), Stanford University (US)
Good health and well-being
Openalex Percentile: Top 16%
Gastrointestinal motility and disorders
1.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.